SUPN News and Press, Supernus Pharmaceuticals Inc. From 11/09/20

Supernus Pharmaceuticals (SUPN) says it received a complete response letter regarding its new drug application for SPN-812 for the treatment of ADHD in pediatric patients 6-17 years old.The FDA says the application is not ready for approval in its present form, citing Superna's in-house labor...

ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced regulatory updates for SPN-812 (viloxazine...

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2020 Earnings Conference Call November 04, 2020, 9:00 AM ET Company Participants Peter Vozzo - IR, Westwicke Jack Khattar - President and Chief Executive Officer Gregory Patrick - Retiring Chief Financial Officer James Kelly - New Chief Financial Offic...

Image source: The Motley Fool. Supernus Pharmaceuticals Inc (NASDAQ: SUPN) Q3 2020 Earnings Call Nov 4, 2020 , 9:00 a.m. ET Operator Continue reading For further details see: Supernus Pharmaceuticals Inc (SUPN) Q3 2020 Earnings Call Trans...

Gainers: Biogen (BIIB) +40%.Cassava Sciences (SAVA) +26%.Athira Pharma (ATHA) +25%.Digirad (DRAD) +22%.Super Micro Computer (SMCI) +21%.Caesarstone (CSTE) +19%.XPeng (XPEV) +19%.Prothena (PRTA) +18%.TravelCenters of America (TA) +18%.Supernus Pharmaceuticals (SUPN) +18%.Losers: Repr...

Gainers: Biogen (BIIB) +43%, Digirad (DRAD) +28%, Supernus Pharmaceuticals (SUPN) +21%, Jupiter Wellness (JUPW) +3%, Cassava Sciences (SAVA) +13%.Losers: Repro Med Systems (KRMD) -28%, Aptevo Therapeutics (APVO) -13%, Allogene Therapeutics (AL...

Gainers: [[DRAD]] +40.0%. [[SUPN]] +17.8%. [[SMCI]] +13.2%. [[ITUB]] +6.7%. [[KE]] +6.2%.Losers: [[NBR]] -12.8%. [[TRHC]] -8.6%. [[MRCY]] -7.4%. [[CLW]] -6.6%. [[CARG]] -5.5%. For further details see: DRAD, SUPN, NBR and CLW among after-hours movers

Supernus Pharmaceuticals (SUPN): Q3 GAAP EPS of $0.74 beats by $0.47.Revenue of $155.14M (+51.9% Y/Y) beats by $24.38M.Raises 2020 Guidance: Net product sales increased to $500-$525M from $460-500M, and operating earnings of $145-$160M from $90-110M.Shares +6.67%.Press Release For further d...

Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 million Q3 2020 operating earnings of $56.1 million On track to initiate commercial launch of SPN-812 in January 2021, if approved by the FDA Topline data from ...

Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to announce Q3 earnings results on Tuesday, November 3rd, after market close.The consensus EPS Estimate is $0.27 (-50.0% Y/Y) and the consensus Revenue Estimate is $130.76M (+28.0% Y/Y).Over the last 2 years, SUPN has beaten EPS estimates 75...